Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. reports news on its radiopharmaceutical business, including diagnostic imaging agents, radiotherapeutic assets, regulatory decisions and financial results. The company organizes revenue around Radiopharmaceutical Oncology, Precision Diagnostics and Strategic Partnerships and Other Revenue, with products used by hospitals, independent imaging centers, government facilities and distribution partners in the United States and abroad.
Recurring updates include quarterly earnings, business guidance, FDA activity for products such as PYLARIFY TruVu, PYLARIFY, Lutetium Lu 177 Dotatate (PNT2003) and LNTH-2501, share repurchases, investor presentations and strategic updates involving radiodiagnostics and radiotherapeutic programs.
Lantheus (NASDAQ:LNTH) will present new radiopharmaceutical data at the 2026 ASCO Annual Meeting, held May 29–June 2, 2026 in Chicago.
Presentations include a Phase 1/2 study of LNTH-2403 in relapsed/refractory osteosarcoma and a publication-only abstract on real-world use of piflufolastat F 18 in early-stage prostate cancer.
Lantheus (NASDAQ: LNTH) reported Q1 2026 revenue of $377.3M and GAAP net income of $118.4M. GAAP fully diluted EPS was $1.80 versus $1.02 a year earlier; adjusted EPS was $1.46. The company received FDA approval for PYLARIFY TruVu with a phased launch planned in Q4 2026 and achieved tentative approval for PNT2003. Cash and equivalents totaled $498.6M, including $31.4M from the SPECT divestiture. Full-year 2026 guidance was reaffirmed at $1.4B–$1.45B revenue and adjusted EPS $5.00–$5.25.
Lantheus (NASDAQ: LNTH) will host its First Quarter 2026 earnings conference call and webcast on May 7, 2026 at 8:00 a.m. ET to discuss financial results and provide a business update.
Registration is required at https://investor.lantheus.com/news-events/calendar-of-events. A replay will be available about two hours after the webcast and archived on the same page for at least 30 days.
Lantheus (NASDAQ: LNTH) said the FDA extended the PDUFA date for LNTH-2501 (Gallium 68 edotreotide) by three months to June 29, 2026. The extension allows additional review of manufacturing information and is a standard delay not related to efficacy or safety.
Lantheus (NASDAQ: LNTH) announced FDA approval of PYLARIFY TruVu (piflufolastat F 18), a new formulation of its PSMA PET imaging agent designed for larger batch production and broader patient access. The product, approved via the 505(b)(2) pathway relying on OSPREY and CONDOR data, is expected to launch in 4Q 2026 with a phased geographic rollout. More than 760,000 patients have received PSMA PET scans with PYLARIFY since May 2021. TruVu aims to improve stability at higher radioactive concentrations to enable larger batches and wider distribution.
Lantheus (NASDAQ: LNTH) received FDA tentative approval for its ANDA of Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent to LUTATHERA®, on March 2, 2026. The tentative approval confirms the ANDA meets statutory requirements but full approval awaits expiration of a 30-month stay in June 2026.
The company licensed exclusive worldwide rights to PNT2003 from POINT Biopharma in December 2022; POINT was later acquired by Eli Lilly. Lantheus says it expects to seek final approval and make PNT2003 available to patients pending regulatory clearance.
Lantheus (NASDAQ: LNTH) reported Q4 2025 worldwide revenue of $406.8 million and full year 2025 revenue of $1.54 billion. GAAP diluted EPS was $0.82 in Q4 and $3.41 for FY2025; adjusted diluted EPS were $1.67 and $6.08, respectively.
The company completed acquisitions, repurchased shares, divested its legacy SPECT business, and issued FY2026 guidance: $1.4–1.45 billion revenue and $5.00–5.25 adjusted EPS.
Lantheus (NASDAQ: LNTH) announced that Mary Anne Heino, Executive Chairperson and CEO, will present at two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 11:10 a.m. ET and Leerink Global Healthcare Conference on March 10, 2026 at 8:00 a.m. ET.
Live webcasts will be accessible via the Investors section of the company's website, with replays available for at least 30 days following each presentation.
Lantheus (NASDAQ: LNTH) will host a conference call and webcast at 8:00 a.m. ET on February 26, 2026 to discuss fourth quarter and full year 2025 financial and operating results. Participants should register online and are encouraged to register 15 minutes early to avoid delays.
A replay will be available approximately two hours after the webcast and archived on the events page for at least 30 days. Access registration at the company events calendar.
Lantheus (NASDAQ: LNTH) announced on January 2, 2026 that it has completed the sale of its SPECT business to SHINE Technologies. The divestiture transfers the SPECT diagnostic agents TechneLite, NEUROLITE, Xenon Xe-133, and Cardiolite, the portion of the North Billerica, Massachusetts campus that manufactures SPECT products, and SPECT-related Canadian operations to SHINE.
With the SPECT business closed, Lantheus will concentrate on its commercial PET radiodiagnostics and microbubbles and continue advancing its radiopharmaceutical pipeline. Financial, legal, and tax advisors to Lantheus on the transaction were disclosed.